Morris, J A <br/><br/>
Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.  [electronic resource] 

 -  Clinical transplantation  Jun 2005 
 - 340-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0902-0063 
<br/><br/><label>Standard No.: </label>10.1111/j.1399-0012.2005.00344.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Daclizumab<br/>Female<br/>Graft Rejection--prevention & control<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Immunosuppressive Agents--therapeutic use<br/>Kidney Transplantation--immunology<br/>Male<br/>Middle Aged<br/>Survival Analysis